QDEL Strangle Strategy
QDEL (QuidelOrtho Corporation), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems.
QDEL (QuidelOrtho Corporation) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $753.5M, a beta of 0.74 versus the broader market, a 52-week range of 9.92-35.58, average daily share volume of 2.2M, a public-listing history dating back to 1991, approximately 7K full-time employees. These structural characteristics shape how QDEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.74 places QDEL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on QDEL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current QDEL snapshot
As of May 15, 2026, spot at $10.45, ATM IV 96.00%, IV rank 28.28%, expected move 27.52%. The strangle on QDEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on QDEL specifically: QDEL IV at 96.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a QDEL strangle, with a market-implied 1-standard-deviation move of approximately 27.52% (roughly $2.88 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QDEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on QDEL should anchor to the underlying notional of $10.45 per share and to the trader's directional view on QDEL stock.
QDEL strangle setup
The QDEL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QDEL near $10.45, the first option leg uses a $10.97 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QDEL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QDEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $10.97 | N/A |
| Buy 1 | Put | $9.93 | N/A |
QDEL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
QDEL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on QDEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on QDEL
Strangles on QDEL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QDEL chain.
QDEL thesis for this strangle
The market-implied 1-standard-deviation range for QDEL extends from approximately $7.57 on the downside to $13.33 on the upside. A QDEL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current QDEL IV rank near 28.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QDEL at 96.00%. As a Healthcare name, QDEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QDEL-specific events.
QDEL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QDEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QDEL alongside the broader basket even when QDEL-specific fundamentals are unchanged. Always rebuild the position from current QDEL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on QDEL?
- A strangle on QDEL is the strangle strategy applied to QDEL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With QDEL stock trading near $10.45, the strikes shown on this page are snapped to the nearest listed QDEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are QDEL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the QDEL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 96.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a QDEL strangle?
- The breakeven for the QDEL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QDEL market-implied 1-standard-deviation expected move is approximately 27.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on QDEL?
- Strangles on QDEL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QDEL chain.
- How does current QDEL implied volatility affect this strangle?
- QDEL ATM IV is at 96.00% with IV rank near 28.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.